Interview Process At Ranbaxy
Under the Guidance of
Ranbaxy Laboratories Limited:
Ranbaxy is one of India's largest pharmaceutical companies. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. The company went public in 1973, and Japanese company Daiichi Sankyo gained majority control in 2008.
Milestones in Ranbaxy’s Path:
The year 1994 marked three distinct changes including the withdrawal of contract with Eli Lily, establishing of separate head quarters in the United Kingdom and USA and the beginning of functioning at the Gurgaon plant. By now the company had established itself in Africa, India, China, US, and UK. In 2000, the company entered, the German markets by acquiring Bayer’s generic business. In 2003,Ranbaxy received the prestigious The Economic Times Award for Corporate Excellence for ‘The Company of the Year, 2002-2003’. Ranbaxy acquires Be Tabs pharmaceuticals, Terapia and acquires unbranded generic business of GSK in Spain and Italy. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., first by purchasing 34.8% of the total stakes followed by 64.2% in November 2008, to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing. An interesting point to note is that throughout history, Ranbaxy has grown through Mergers and Acquisitions. This can be attributed to the increasing levels of inward FDI, the growth in the Indian economy, and relaxation of the constraints on Indian companies, which wanted to expand overseas.
Today Ranbaxy is one of India's largest pharmaceutical company, and is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.
The Company’s business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of it’s around 14,000 strong multicultural workforce comprising of over 50 nationalities, Ranbaxy continues to aggressively pursue its mission ‘To become a Research-based International Pharmaceutical Company’. Company Vision:
Achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets.
“To become a Research-based International Pharmaceutical Company”
The vision and the mission statements of Ranbaxy make it clear that, it is working on a strategy that strikes out a balance between an innovation based differentiation strategy and a cost leadership strategy. It therefore works on a Hybrid model, a unique and pro-active model that has potential to provide an excellent mix of innovative and affordable quality medicine to people around the world. The model represents a great opportunity for synergy benefits to both Ranbaxy and Daiichi Sankyo. The strategy for optimum utilization of the Ranbaxy NDDR (discover R and D) resource has also been agreed on.
Financials of Ranbaxy:
Ranbaxy is an Rs.4000crore company with a profit of Rs.571.98crore in 2010. This was after a loss of Rs.1044.88crore last year. According to the financial report, the company is growing...
References: 1. http://indolinkenglish.wordpress.com/2010/04/29/ranbaxy-to-step-up-head-count-launch-new-drugs
2. Arthur, Diane. Recruiting, Interviewing, Selecting & Orienting New Employees. New Delhi: Rekha Printers Private Limited, 2010.
Please join StudyMode to read the full document